Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
During this Masterclass, expert faculty will discuss the links between sleep disorders and cardiometabolic health, as well as practical approaches for screening, referral, or treatment.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging. During this case, you will have a chance to explore treatment decisions to decrease overall cardiorenal risk in a complex patient, accompanied by expert commentary and brief review of evidence with SGLT-2is and GLP-1 RAs across cardiovascular outcomes trials.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Osteoporosis is a prevalent condition and a major health problem, but particularly more in postmenopausal women. Approximately 2 million osteoporosis-related fractures occur annually in the US, and more than 70% of these occur in women. Furthermore, osteoporosis carries a significant burden, estimated to be at $57 billion in 2018 and projected to reach more than $95 billion by year 2040.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pulmonary arterial hypertension (PAH) is a complex and heterogenous disease, which remains challenging to diagnose and treat. During this webinar series, you will have a chance to hear from leading PAH experts about the screening, diagnosis, and treatment of PAH, as well as recent advances in the treatment landscape and their interpretation to patient care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Diabetic kidney disease (DKD) remains one of the major causes of morbidity and mortality in patients with type 2 diabetes. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including targeting mineralocorticoid receptor overactivation with novel, non-steroidal mineralocorticoid receptor antagonists (MRAs).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a presentation at the 2021 CMHC Spring meeting, offers a concise overview of recent trials and developments in antithrombotic and antiplatelet therapy in high-risk cardiometabolic patients with coronary artery disease (CAD) or peripheral artery disease (PAD). 

Pages